Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sulfasalazine
Drug ID BADD_D02093
Description A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Indications and Usage For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
Marketing Status Prescription; Discontinued
ATC Code A07EC01
DrugBank ID DB00795
KEGG ID D00448
MeSH ID D012460
PubChem ID 5339
TTD Drug ID D02ZTJ
NDC Product Code 68071-4215; 23155-019; 70518-1829; 50090-0086; 49964-0018; 43353-495; 63629-5688; 70518-0185; 51927-0054; 51927-0081; 0591-0796; 0013-0101; 59762-0104; 38779-0176; 0013-0102; 50268-730; 59116-0632; 62705-0222; 62991-2704; 57294-021; 59116-0631; 71610-577; 59762-5000; 59116-0633; 59116-0630; 62135-960; 51552-1044; 50090-2013; 49452-7523; 68022-7065; 70518-2342
Synonyms Sulfasalazine | Salicylazosulfapyridine | Sulphasalazine | Salazosulfapyridine | Pyralin EN | Azulfadine | Azulfidine EN | Azulfidine | Asulfidine | Colo-Pleon | Colo Pleon | Pleon | Ulcol | Sulfasalazin medac | Sulfasalazin-Heyl | Sulfasalazin Heyl | Sulfasalazine FNA | Ucine | Salazopyrin | ratio-Sulfasalazine | ratio Sulfasalazine
Chemical Information
Molecular Formula C18H14N4O5S
CAS Registry Number 599-79-1
SMILES C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Leukopenias NECCytochrome P450 1A2P05177Not Available11600468; 11856081; 11600469
VasculitisMyeloperoxidaseP05164T234717913504; 7913503; 8102951; 7914458; 8624621; 7869327; 7835022; 8095074; 8624617
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Developmental delay08.01.03.0370.001382%Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.002072%Not Available
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic07.02.01.002; 24.07.02.004--Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.001382%
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.011052%Not Available
Drug hypersensitivity10.01.01.0010.252817%Not Available
Dry mouth07.06.01.002--
Dysgeusia07.14.03.001; 17.02.07.003--
Dyspepsia07.01.02.0010.006217%
Dysphagia07.01.06.003--
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.004--
Dyspnoea22.02.01.004; 02.01.03.002--
Ear disorder04.03.01.001--Not Available
Ear pain04.03.01.0030.001382%
Eczema23.03.04.0060.001382%
Encephalopathy17.13.02.001--
Eosinophilia01.02.04.0010.004145%
Eosinophilic myocarditis02.04.03.002; 01.02.04.0070.000721%Not Available
Eosinophilic pneumonia01.02.04.003; 22.01.01.0040.004835%Not Available
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.003454%
Factor II deficiency03.15.01.004; 01.01.01.007--Not Available
Faeces discoloured07.01.03.0020.002072%Not Available
Fatigue08.01.01.002--
Febrile neutropenia08.05.02.004; 01.02.03.0020.002763%
Feeling abnormal08.01.09.014--Not Available
Feeling jittery08.01.09.0160.002072%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 15 Pages